Promoter hypermethylation has become apparent as a common mechanism of gene silencing in cancer. Based on our published microarray expression data, we noticed a prominent downregulation of ID4 in gastric adenocarcinoma. The dense 5 0 CpG island covering the previously mapped upstream promoter of ID4 has prompted us to relate its downregulation to promoter hypermethylation. ID proteins are distinct members in the helix-loop-helix family of transcriptional regulators, which modulate various key developmental processes. Emerging data have suggested the involvement of ID genes in tumorigenesis. In this study using bisulfite genomic sequencing, we have found hypermethylation of ID4 promoter in most gastric cancer cell lines and 30% of primary tumors. This correlated with decreased level of ID4 expression. Restoration of ID4 expression in various gastric cancer cell lines was achieved by treatment with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine, which at times required the synergistic action of the histone deacetylase inhibitor trichostatin A, but not with trichostatin A alone. Re-expression was accompanied by the corresponding ID4 promoter demethylation. Furthermore, we have found significant association of ID4 promoter methylation with hMLH1 promoter methylation (P ¼ 0.008) and microsatellite instability (P ¼ 0.006). Overall, our results have shown that transcriptional silencing of ID4 is related to the aberrant methylation of its promoter in gastric cancer. The significant association of ID4 and hMLH1 promoter hypermethylation suggested that ID4 may also be among the genes being targeted in the CpG island methylator phenotype tumorigenic pathway.
Promoter hypermethylation has become apparent as a common mechanism of gene silencing in cancer. Based on our published microarray expression data, we noticed a prominent downregulation of ID4 in gastric adenocarcinoma. The dense 5 0 CpG island covering the previously mapped upstream promoter of ID4 has prompted us to relate its downregulation to promoter hypermethylation. ID proteins are distinct members in the helix-loop-helix family of transcriptional regulators, which modulate various key developmental processes. Emerging data have suggested the involvement of ID genes in tumorigenesis. In this study using bisulfite genomic sequencing, we have found hypermethylation of ID4 promoter in most gastric cancer cell lines and 30% of primary tumors. This correlated with decreased level of ID4 expression. Restoration of ID4 expression in various gastric cancer cell lines was achieved by treatment with the DNA methyltransferase inhibitor 5-aza-2 0 -deoxycytidine, which at times required the synergistic action of the histone deacetylase inhibitor trichostatin A, but not with trichostatin A alone. Re-expression was accompanied by the corresponding ID4 promoter demethylation. Furthermore, we have found significant association of ID4 promoter methylation with hMLH1 promoter methylation (P ¼ 0.008) and microsatellite instability (P ¼ 0.006). Overall, our results have shown that transcriptional silencing of ID4 is related to the aberrant methylation of its promoter in gastric cancer. The significant association of ID4 and hMLH1 promoter hypermethylation suggested that ID4 may also be among the genes being targeted in the CpG island methylator phenotype tumorigenic pathway. Oncogene (2003 Oncogene ( ) 22, 6946-6953. doi:10.1038 Keywords: ID4; hMLH1; microarray; promoter methylation; gastric adenocarcinoma Gastric adenocarcinoma remains one of the most common cancers worldwide with exceptionally high incidence in some Asian and European countries. To advance understanding of gastric cancer on the molecular genetics level, we have previously performed gene expression profiling on a large panel of gastric adenocarcinomas, non-neoplastic gastric mucosa and gastric cancer cell lines Leung et al., 2002) . During ongoing data analysis, we observed an intriguing differential expression pattern for a family of transcription factors, the ID family. ID proteins were identified a decade ago as distinct members in the helixloop-helix (HLH) proteins family. By forming heterodimers with the basic HLH (bHLH) proteins, ID proteins are known to modulate various key developmental processes (reviewed in Massari and Murre, 2000) . Currently, four known human ID proteins have been identified. Expression studies in embryonic tissues showed that ID proteins play critical roles in early embryonic development (Jen et al., 1996 (Jen et al., , 1997 Kee and Bronner-Fraser 2001) . They are also involved in angiogenesis, lymphocyte development, cell cycle control and cellular senescence as recently reviewed (Benezra et al., 2001; Rivera and Murre 2001; Zebedee and Hara 2001) . Emerging data have also suggested the involvement of ID proteins in neoplastic processes. Increased ID1 and ID2 expression has been reported in various tumor types, including adenocarcinomas arising from the colon and pancreases (Kleeff et al., 1998; Wilson et al., 2001) . Transgene expression of ID1 and ID2 in mice has resulted in tumor formation in the intestinal epithelium and lymphoid organs, respectively (Wice and Gordon 1998; Morrow et al., 1999) . Expression of ID3 has been more variable with studies reporting both upregulation (Wilson et al., 2001; Vandeputte et al., 2002) and downregulation (Arnold et al., 2001; Deleu et al., 2002) in different tumor types. Little is known, however, about the expression, regulation and potential roles of ID4 in the carcinogenic process.
Data from our array showed that the expression of ID1 in gastric cancer is very similar to those reported in other tumor types (Figure 1 ). We observed a general increased expression in most primary gastric cancers and cell lines compared with the non-neoplastic mucosa. ID2 showed a similar trend of low expression in nonneoplastic mucosa, and elevated levels in a proportion of gastric cancers and cell lines. By contrast, ID3 and ID4 showed a reversed pattern of expression. In particular, ID4 showed a uniformly high level of expression in non-neoplastic mucosa and very low expression levels in about one-third of primary gastric cancers. Low expression levels of ID4 in seven of the eight gastric cancer cell lines were also noted (Figure 1 ). Upon examination of ID4 genomic structure, a dense 5 0 CpG island was located covering the previously mapped upstream ID4 promoter, while no 5 0 CpG island was noted for ID3. We thus hypothesized that promoter hypermethylation might be involved in the downregulation of ID4 in gastric cancer.
Relative expression levels of ID4 in gastric cancer cell lines were independently assessed by RT-PCR. The highest level of expression was found in SNU1 and an additional gastric cancer cell line MKN74, which had not been acquired at the time of the profiling study. Low level of ID4 expression was noted for NUGC3, and no detectable level of ID4 was found in the rest of the gastric cancer cell lines (Figure 1 ). The RT-PCR results were thus in good concordance with the expression array data. Based on this observation, we proceeded to examine the methylation profiles of ID4 promoter in these cell lines.
The 5 0 CpG island of ID4 is about 2 kb, which extends from the upstream promoter all through exon 1 ( þ 1 to þ 824), intron 1 (388 bp), exon 2 ( þ 825 to þ 883) and intron 2 (567 bp). A set of neutral primers, which would amplify both the methylated and unmethylated alleles of the bisufite-modified DNA, was designed flanking the region between nucleotide positions À189 and þ 128, which contains 37 CpG sites (Figure 2 ). This region was chosen as it covers the minimal promoter, which was Figure 1 Expression data of ID genes in gastric adenocarcinomas. Top panel is a color display of the relative expression level of the four ID genes. Data were extracted from the global gene expression profiles as previously published Leung et al., 2002) . For each gastric tissue sample, the relative abundance of each transcript, in relation to its mean abundance across all tissue samples, is depicted according to the color scale shown on the right. Red and green color denote above and below mean expression within the total population, respectively. Grey color indicates missing or excluded data (array data for MKN74 were not available). For the gastric cancer cell lines, the relative abundance of each transcript to the mean abundance across all tissue samples and cell lines is shown. Lower panel shows expression data of ID4 in gastric cancer cell lines, as measured by microarray in comparison to that determined by RT-PCR. Expression level of the housekeeping gene porphobilinogen deaminase (PBGD) was showed for reference. The corresponding promoter methylation status (M ¼ methylated, U ¼ unmethylated) for each cell line as determined by bisulfite genomic sequencing is also listed. Full experimental details of both cDNA array experiments have been published and the data sets are available for public review via the internet links http://genome-www.stanford.edu/GCcells and http://genome-www.stanford.edu/Gastric_Can-cer. Briefly, poly-A þ mRNA extracted from the gastric cancer cell lines and gastric tissue samples were hybridized against a common reference mRNA to the cDNA microarray containing 44 500 cDNA clones, which represent about 30 300 unique genes. For RT-PCR analysis, total RNA was extracted using TRIzol LS reagent (Invitrogen, Carlsbad, USA) and 1 mg of total RNA was subjected to DNaseI (Invitrogen) treatment before reverse transcribed with Superscript II (Invitrogen) in the presence of 200 ng of random hexamer. A volume of 2 ml of the 1 : 10 diluted RT product was used as template in subsequent PCR amplifications. Primers specific for the amplification of ID4 transcripts were ID4-F (5 0 TCACTGCGCTCAACACCGACCC3 0 ) and ID4-R (5 0 TTCCCCCTCCCTCTCTAGTGCTCCTG3 0 ). Amplification was carried out in 20 ml reaction containing 0.4 mm of each primer, 1 mm Mg 2 þ , 0.2 mm dNTPs and 1 U of Platinum Taq DNA polymerase (Invitrogen) in 1XPCR buffer. In total, 35 amplification cycles (941C-30 s, 641C-30 s, 721C-30 s) were performed with an initial denaturation at 941C for 3 min and a final extension at 721C for 10 min. The housekeeping gene PBGD was amplified with primers PBGD-F (5 0 TCGCATACAGACGGACAGTGTGGTGG3 0 ) and PBGD-R (5 0 CCGAAGCCGGGTGTTGAGGTTT3 0 ). Amplification condition is the same as that for ID4 except with the use of 0.3 mm of primers, 1.5 mm Mg 2 þ and 601C annealing temperature. Details of bisulfite genomic sequencing are described in Figure 2 ID4 down regulation in gastric adenocarcinoma ASW Chan et al Figure 2 Methylation profiles of ID4 promoter region. Top panel shows the 5 0 gene structure of ID4 and the region for bisulfite genomic sequencing in relation to the major transcription start site (TSS). Distribution of the 37 CpG sites examined is shown in rough proportion as black rectangles. Selected bisulfite genomic sequence tracings covering the minimal promoter (À48 to þ 32) are shown to illustrate methylation (M), unmethylation (U) and minimal methylation (mm). Blue bar highlights the TATA box, red arrow indicates the TSS and black asterisks locate the CpG sites. For direct bisulfite genomic sequencing of PCR products, genomic DNA was extracted using standard phenol/chloroform methodology and subjected to bisulfite conversion based on previously published protocol (Paulin et al., 1998) . Briefly, 2 mg of DNA was denatured in 0.3 n NaOH followed by conversion in urea/metabisulfite solution with hydroquinone for 15 h at 551C. DNA was then purified using High Pure PCR Product Purification kit (Roche, Basel, Switzerland). Conversion was completed by incubation in 0.3 n NaOH for 15 min at 371C. DNA was then precipitated in ethanol and resuspended in 100 ml of 10 mm Tris-HCl, pH 8.5. A measure of 1-4 ml of the bisulfite-modified DNA was used as template for initial PCR amplification with neutral primers ID4-NP-F (5 0 TTTTATTYGGGTAGTYGGATTTTTYGTTTTTTAGTAT3 0 ) and ID4-NP-R (5 0 CCCACCCRAATATCCTAATCACTCCCTTC3 0 ), with Y ¼ C or T, R ¼ G or A. Amplification condition was the same as that for PBGD except with the use of 2 mm Mg 2 þ and 40 amplification cycles. To prepare PCR products for direct sequencing, excess PCR primers and dNTPs were cleaned up by EXO1 and SAP digestion using PCR Product Pre-Sequencing kit (USB, Cleveland, USA). Cleaned PCR products were then sequenced using DYEnamic ET Terminator Cycle Sequencing kit (Amersham, Little Chalfont, England). Cycling program includes 25 cycles of 951C-20 s and 601C-1 min. Samples were then resolved in 4% acrylamide gel and signals detected with the ABI377 sequencer ID4 down regulation in gastric adenocarcinoma ASW Chan et al previously mapped between À48 and þ 32 with reference to the major transcription start site ( þ 1) (Pagliuca et al., 1998) . By direct bisulfite genomic sequencing of this PCR-amplified region, the 11 gastric cancer cell lines showed three distinct patterns of methylation. Nine cell lines (all except SNU1 and MKN74) showed complete methylation at all the 37 CpG sites assessed. The sequence tracings covering the minimal promoter of MKN45 was shown in Figure 2 as an example of this methylation pattern. ID4 expression in all of these cell lines was low or undetectable ( Figure 1 ). Among the remaining two cell lines, SNU1 was completely unmethylated within this region. For MKN74, no methylation was found from sites #1 to #29, which included the minimal promoter ( Figure 2) ; and only low level of methylation was noted at sites #30 and distally that involved a region downstream of the transcription start site extending into exon 1. Both cell lines expressed ID4 at a relatively high level (Figure 1 ). Thus, there was a clear inversed correlation of ID4 promoter methylation and ID4 expression in gastric cancer cell lines.
To ascertain the association of promoter methylation with ID4 downregulation, three gastric cancer cell lines (AGS, BCG823 and PAM82) were treated with the DNA demethylating agent 5-aza-2 0 -deoxycytidine (5Aza-dC). Effective induction of ID4 was achieved in AGS. While no detectable level of ID4 was found in the untreated AGS sample by RT-PCR, strong expression was detected after treatment (Figure 3a) . However, 5Aza-dC alone failed to restore expression of ID4 in BCG823 and PAM82 cells. As trichostatin A (TSA) has been shown to act synergistically with 5Aza-dC in restoring expression of densely methylated genes (Cameron et al., 1999), we treated these cells with 5Aza-dC and TSA in combinations. Re-expression of ID4 was then detected by RT-PCR in these cell lines after treatment with both drugs, but not with either alone. Data for PAM82 are shown in Figure 3a . Demethylation of ID4 promoter in all the three cell lines was confirmed by bisulfite genomic sequencing with the reemergence of 'T' peaks at various CpG sites (Figure 3b) . In contrast to a previous study, which showed no apparent effect of TSA in enhancing 5Aza-dC-induced demethylation (Cameron et al., 1999) , we did observe a slight effect of TSA in demethylation following the 5Aza-dC treatment in both cell lines. This was indicated by the more obvious 'T' peaks at various CpG sites in samples treated with both 5Aza-dC and TSA compared to that with 5Aza-dC only. The sequence tracings of PAM82 are shown in Figure 3b as an example.
We noticed here the differential sensitivity of different cell lines to 5Aza-dC. With reference to previous studies with proviral sequences-transfected cells, the responsiveness of gene induction by 5Aza-dC or TSA would decrease over time as the cells were passaged, and this was directly correlated with the level of methylation. After certain passages, the cells could become completely refractory to induction by either drug alone. At this point, re-expression can only be achieved by pretreating cells with 5Aza-dC followed by TSA (Lorincz et al., 2000) . Our findings may suggest that methylation of ID4 promoter in BCG823 and PAM82 is more complete than that of in AGS, and the expression of ID4 in AGS could be more 'leaky'. Indeed, by using 10 times more template in RT-PCR, weak expression of ID4 could be detected in AGS but still not in BCG823 and PAM82 (data not shown).
As the association of ID4 promoter hypermethylation and its corresponding downregulation have been demonstrated in vitro, its involvement in gastric adenocarcinoma was then studied. Initially, 34 non-neoplastic gastric mucosa were examined. These were taken from the same gastrectomy specimens as the tumors, and they showed variable degrees of gastritis and intestinal metaplasia. Methylation at each individual CpG site was recorded (Figure 4) . Among the 34 cases, 13 showed no methylation at all the 37 sites, while 18 showed isolated minimal methylation (presence of a small population of methylated DNA, constituting less than one-third of the total population) mostly clustered at sites #30 and distally, similar to that found in MKN74 cells. The sequence tracings of a representative case (HKG41N) are shown in Figure 2 . The remaining three cases (9%) showed minimal methylation involving most CpG sites (e.g. HKG21N in Figure 2 ) with one case also showing definitive methylation at sporadic sites outside of the minimal promoter (Figure 4 ). Histological review of these three cases showed presence of gastritis in all, with superimposed intestinal metaplasia in two. However, they were morphologically indistinguishable from those cases without ID4 promoter methylation yet showing similar changes. As a result, the majority (31/ 34, 91%) of non-neoplastic gastric mucosa showed no methylation within the minimal promoter region. Meanwhile, we used another set of primers to analyse 22 CpG sites located further downstream within exon 1 ( þ 471 to þ 640) and found that 58% of the nonneoplastic gastric mucosa were methylated in this second region (data not shown). Thus, normal methylation seems to exist within the body of ID4 gene distal to the minimal promoter.
With no significant methylation detected within ID4 minimal promoter in the non-neoplastic gastric mucosa, tumor tissues were examined next. In total, 90 tumors were used in the expression array, of which 14 were excluded in this study due to the absence of usable expression data for ID4 or failure in generating PCR products for bisulfite genomic sequencing. Among the remaining 76 primary gastric cancers, three distinct groups of methylation pattern could be identified (Figure 4) . Twenty-three tumors (23/76, 30%) showed definitive methylation involving most CpG sites, hereby referred to as the methylated group (Figure 2) . Twentyseven tumors (27/76, 36%) demonstrated either a complete unmethylated pattern (21/27), or with minimal methylation mostly limited to site #30 and distally (6/27), similar to that seen in many of the non-neoplastic gastric mucosa, hereby referred to as the unmethylated group (Figure 2) . However, in 26 tumors (26/76, 34%), a more variegated methylation pattern was noted, hereby referred to as the variegated methylated group. Within this group, some cases showed minimal methylation at most CpG sites; while others showed, in addition, definitive methylation at sporadic sites, but mostly sparing the minimal promoter region. This pattern has been observed in the three non-neoplastic gastric mucosa (Figure 4) . Statistical analysis using numeric data from the expression array showed that tumors of the methylated group expressed ID4 at a significantly lower level than that of the unmethylated group (Student's t-test, Po0.001) and the variegated methylated group (P ¼ 0.002). On the contrary, no significant difference in ID4 expression level was found between the variegated methylated group and the unmethylated group (P ¼ 0.55) (mean log base 2 expression for methylated group ¼ À0.6170.68; for unmethylated group ¼ 0.27 0.65; for variegated methylated group ¼ 0.0870.79). Based on these statistical data, the significance of the variegated pattern of methylation is doubtful, as there was no significant reduction of ID4 expression level when compared with tumors showing no methylation.
In a recent review, Turker speculated that the establishment of methylation is a dynamic process involving the maintenance of open chromatin by active transcription and the spreading of methylation from pre-existing foci, during which a shifting methylation boundary can exist before the complete establishment of a stable methylated state (Turker, 2002) . The variegated methylation patterns we captured in some of our gastric cancer samples could be the representatives in the midst of this dynamic process. It is of interest to note that among this group of tumors with variegated methylation patterns, the CpG sites encompassing the minimal promoter (sites 18-28) tended to show only minimal methylation, while the more definite methylation signals were detected upstream or downstream from this subregion (Figure 4 ). This observation seems to confirm the significance of this minimal promoter region in regulating ID4 expres- promoter. For treatment with 5Aza-dC alone, an 8-day treatment protocol was applied as previously published (Veigl et al., 1998) . Briefly, 10 5 cells were seeded per T-75 culture flask on day 0. Cells were then treated with 5Aza-dC (Fluka, Buchs, Switzerland) at the final concentrations of 1, 2, 3 and 5 mg/ml (1 mg/ml ¼ 4.4 mm) on days 2 and 5 for 24 h. The medium was changed on days 3 and 6. On day 8, cells were harvested for DNA and RNA. For the combined 5Aza-dC and TSA treatment, a 3-day course was applied (Cameron et al., 1999) . Briefly, 8 Â 10 5 cells were seeded per 90 mm plate on day 0. On day 1, 5Aza-dC was added at the final concentrations of 5 mg/ml (22 mm) and 10 mg/ml (44 mm) using a 1 mg/ml stock dissolved in water. On day 2, TSA (Sigma, St Louis, USA) was added at a final concentration of 1 mm with a 1 mm stock dissolved in ethanol. On day 3, cells were harvested for DNA and RNA. Mock-treated controls were performed concurrently ID4 down regulation in gastric adenocarcinoma ASW Chan et al sion as determined by deletion constructs experimentation (Pagliuca et al., 1998) . Previously Toyota et al. (1999a) have reported the existence of CpG island methylator phenotype (CIMP) in colorectal cancer, in which a strong association between CIMP þ tumors and hMLH1 promoter hypermethylation was found. A similar trend has also been observed in gastric adenocarcinoma by the same group (Toyota et al., 1999b) . Based on these data, we proceeded to examine the methylation status of hMLH1 promoter in this series of gastric adenocarcinomas. In total, 11 CpG sites were examined within the region from À316 to À133 of hMLH1 gene by bisulfite genomic sequencing as previously described . Our group and others have previously shown that these CpG sites are most critical for transcriptional silencing of this gene (Deng et al., 1999; Yuen et al., 2002) . The methylation patterns of hMLH1 promoter were less complex with either complete methylation, that is, dominant 'C' peaks, or complete unmethylation, that is, dominant 'T' peaks, at all CpG sites (data not shown). Of the 74 tumors (two samples failed to yield a PCR product for sequencing), 19 showed complete methylation within this region, of which 11 overlapped with ID4 promoter hypermethylation ( Table 1 ). The 19 cases of hMLH1 promoter hypermethylated cases all displayed high-level microsatellite instability (MSI-H) and loss of hMLH1 protein. Data from most of these cases have been reported previously (Leung et al., 1999a, b) . There were in addition only two MSI-H cases found without hMLH1 promoter hypermethylation, with one showing ID4 promoter methylation. Thus, methylation of ID4 promoter is significantly associated with hMLH1 promoter hypermethylation (w 2 test with Yates corrections, P ¼ 0.008) and the MSI-H phenotype (P ¼ 0.006). This finding suggested that ID4 maybe among the target genes for hypermethylation and transcriptional silencing in the CIMP þ subgroup of gastric adenocarcinoma.
Promoter hypermethylation is known as an important epigenetic mechanism associated with tumor suppressor Figure 4 Graphic display of the methylation status at individual CpG sites of ID4 upstream region in 76 gastric adenocarcinomas and 34 non-neoplastic gastric mucosa, as determined by bisulfite genomic sequencing. Sequence tracings were reviewed for each sample with methylation status of individual CpG site recorded according to the following grading criteria. A CpG site was graded as unmethylated when there was no detectable 'C' peak (denoted by J); minimally methylated when the 'C' peak was less than 50% the height of the 'T' peak (denoted by ) and methylated when the 'C' peak height reached 50% or above of that of the 'T' peak, that is, methylated 'C' constituting over 33% of the total population (denoted by ) ID4 down regulation in gastric adenocarcinoma ASW Chan et al gene silencing in cancers, and cDNA microarray is best designed to detect alteration of transcription levels of thousands of genes in tissue samples. By combining the results from these two analyses, we have reported for the first time the downregulation of ID4 in a substantial proportion of gastric cancers and demonstrated that this downregulation is correlated to ID4 promoter hypermethylation. Furthermore, we have identified the significant association of ID4 promoter hypermethylation with that of hMLH1 in gastric adenocarcinoma, and thus its possible involvement in the CIMP pathway of gastric cancer development.
Although the precise functional role of ID4 is unclear, the ability of ID proteins in modulating activities of bHLH transcription factors, which are key regulators of cellular differentiation, makes them an attractive target for dysregulation during tumorigenesis. Previous studies have shown that ID1 and ID2 were upregulated in some cancer types, corresponding to their roles in promoting proliferation and inhibiting differentiation. However, it is not uncommon to find genes with disparate functions within the same family. Prominent examples can be found in the BCL2 family of proteins, in which members can mediate either proapoptotic or antiapoptotic effects (reviewed in Cory and Adams, 2002) . Similar scenario seems to exist within the ID family as ID3 has been reported as downregulated in yet other cancer types. Indeed, contrary to ID1 and ID2, ID3 was found to induce, rather than inhibit, differentiation in thymocyte (Bain et al., 1999) . Regarding ID4, known differences in various aspects have distinguished it from other ID members and thus lend support for its unique functional role. These differences include a more restricted expression pattern of ID4 during mouse and avian embryogenesis, which is distinct from the other three ID members (Jen et al., 1996 (Jen et al., , 1997 Kee and BronnerFraser, 2001 ). While ID1, ID2 and ID3 were expressed at very early stage of development, ID4 was expressed later in time and in tissues at more advanced stages of differentiation. In addition, ID4 protein was also found to possess a different degradation pathway when compared with the other three ID proteins (Bounpheng et al., 1999) . Yet the most striking finding was in the study of ID expression during mouse stomach development. ID1, ID2 and ID3 were found to express in the dorsal part of the developing stomach, where cells were proliferating faster to form the stomach curvature, whereas ID4 expression was restricted to the ventral part where cells grow slower (Jen et al., 1996) . Taken together, ID4's restricted expression in the more differentiated tissues during embryogenesis, its association with cells possessing a lower proliferation rate during stomach development, and its downregulation by promoter hypermethylation in gastric cancer call for further investigation for a putative tumor suppressor role of ID4. Indeed, preliminary data have already suggested the involvement of ID4 in the autoregulatory loop with the tumor suppressor BRCA1 (Beger et al., 2001; Welcsh et al., 2002) .
Overall, our study illustrates the power of combining microarray expression data and promoter methylation analysis in deciphering epigenetic mechanisms related to carcinogenesis. Although promoter hypermethylation may not necessarily be the only factor involved in ID4 downregulation, the strong association of the two does support a central role of the former. Given the wellknown example of the two-hit inactivation of hMLH1 in colorectal cancer , additional genetic defects such as deletion or mutations may also contribute to ID4 downregulation or inactivation in cases without promoter hypermethylation. Further studies to identify these genetic changes and the direct interacting partners of ID4 protein will help to clarify the role of ID4 in gastric carcinogenesis. Numbers in brackets are the number of MSI-H cases within the particular group. hMLH1 promoter methylation and MSI data were previously reported for most of these cases (Leung et al., 1999a, b) . ID4 methylated group versus unmethylated and variegated methylated groups combined. ID4 down regulation in gastric adenocarcinoma ASW Chan et al
